Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Simone Augustinus

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0625-4349; OpenAlex author ID A5060704205. Sources: OpenAlex.

Their work

Papers
18 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2022: 1 paper · 2023: 4 papers · 2024: 4 papers · 2025: 6 papers · 2026: 3 papers

Papers 18

  1. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. First author DOI 10.1016/j.hpb.2025.12.035↗
  2. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. First author DOI 10.1093/bjsopen/zrag033↗
  3. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Co-author DOI 10.1097/j.pain.0000000000004059↗
  4. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  5. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  6. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  7. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  8. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  9. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. First author DOI 10.6004/jnccn.2024.7091↗
  10. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  11. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis. First author DOI 10.1097/xcs.0000000000000971↗
  12. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… First author DOI 10.1245/s10434-024-15932-3↗
  13. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… First author DOI 10.1245/s10434-024-16021-1↗
  14. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient p… Co-author DOI 10.1080/0284186x.2023.2273898↗
  15. Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival… Co-author DOI 10.1245/s10434-023-13465-9↗
  16. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette St… Co-author DOI 10.3390/cancers15235603↗
  17. [Nationwide multidisciplinary developments in pancreatic cancer care in the Netherlands]. Co-author PMID 37994711↗
  18. The fear of cancer recurrence and progression in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-022-06887-w↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 14 shared papers, 2022–2026 · strength 2.53
  2. Johanna W. Wilmink · 8 shared papers, 2022–2026 · strength 1.50
  3. Judith de Vos‐Geelen · 7 shared papers, 2022–2026 · strength 1.39
  4. Ignace H. J. T. de Hingh · 7 shared papers, 2022–2026 · strength 1.32
  5. Hjalmar C. van Santvoort · 7 shared papers, 2023–2026 · strength 1.32
  6. Hanneke W.M. van Laarhoven · 7 shared papers, 2022–2026 · strength 1.31
  7. Marjolein Y.V. Homs · 6 shared papers, 2023–2026 · strength 1.25
  8. Izaak Quintus Molenaar · 7 shared papers, 2022–2025 · strength 1.18
  9. Bert A. Bonsing · 6 shared papers, 2023–2026 · strength 1.17
  10. Bas Groot Koerkamp · 6 shared papers, 2023–2025 · strength 1.01
  11. Martijn W.J. Stommel · 5 shared papers, 2024–2026 · strength 0.90
  12. Vincent Erwin de Meijer · 4 shared papers, 2025–2026 · strength 0.83
  13. Pauline A. J. Vissers · 3 shared papers, 2025–2026 · strength 0.67
  14. Thomas F. Stoop · 3 shared papers, 2024–2025 · strength 0.49
  15. Bodil Andersson · 3 shared papers, 2024 · strength 0.48
  16. Karin U. Johansen · 3 shared papers, 2024 · strength 0.48
  17. Tobias Keck · 3 shared papers, 2024 · strength 0.48
  18. Bergþór Björnsson · 3 shared papers, 2024 · strength 0.48
  19. Bobby Tingstedt · 3 shared papers, 2024 · strength 0.48
  20. Ulrich Friedrich Wellner · 3 shared papers, 2024 · strength 0.48
  21. Henry Anthony Pitt · 3 shared papers, 2024 · strength 0.48
  22. Tara M. Mackay · 3 shared papers, 2023–2024 · strength 0.47
  23. Susan van Dieren · 3 shared papers, 2023–2024 · strength 0.45
  24. Stefan A.W. Bouwense · 2 shared papers, 2025–2026 · strength 0.42
  25. Sebastiaan Festen · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.